Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Plasma cell 1

Conditions

Carcinoma, Renal Cell 65Sarcoma 40Neoplasm Metastasis 22Neoplasms 20Ovarian Neoplasms 17Breast Neoplasms 17Carcinoma, Non-Small-Cell Lung 15Recurrence 7Leiomyosarcoma 7Kidney Neoplasms 7Melanoma 6Liposarcoma 6Hemangiosarcoma 6Glioblastoma 6Fallopian Tube Neoplasms 6Thyroid Neoplasms 5Prostatic Neoplasms 5Neurofibrosarcoma 5Lung Neoplasms 5Urinary Bladder Neoplasms 4Solid Tumors 4Sarcoma, Synovial 4Pancreatic Neoplasms 4Osteosarcoma 4Histiocytoma, Malignant Fibrous 4Dermatofibrosarcoma 4Clear-cell metastatic renal cell carcinoma 4Chondrosarcoma, Extraskeletal Myxoid 4Uterine Cervical Neoplasms 3Small Cell Lung Carcinoma 3

Interventions

seclidemstat 2Topotecan 2Cyclophosphamide 2selinexor 1pazopanib 1Zoledronic Acid 1Proton Therapy 1Ifosfamide 1Doxorubicin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Myoepithelioma × pazopanib × Clear all
NCT06239272 2026-05-19

NRSTS2021, A Risk Adapted Study Evaluating Maintenance Pazopanib, Limited Margin, Dose-Escalated Radiation Therapy and Selinexor in Non-Rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS)

St. Jude Children's Research Hospital

Phase 1/2 Recruiting
139 enrolled
Plasma cellSarcoma

Histiocytoma, Angiomatoid Fibrous, Chondrosarcoma, Extraskeletal Myxoid, Fibrosarcoma, Glomus Tumor, Granuloma, Plasma Cell, Hemangiosarcoma, Liposarcoma, Myoepithelioma, Sarcoma, Osteosarcoma, Disorders of Sex Development, Granular Cell Tumor, Neoplasms, Adipose Tissue, Liposarcoma, Myxoid, Dermatofibrosarcoma, Sarcoma, Clear Cell, Smooth Muscle Tumor, Nerve Sheath Neoplasms, Neurofibrosarcoma, Hemangioendothelioma, Epithelioid, Vascular Neoplasms, Solitary Fibrous Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡